Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope.  Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer.  The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. 

Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products.  For more information please visit www.macrocyclics.com.

Nuclear

Health Care

Orano Med

Julien Dodet

Virgil Dodson

Sadaf Qureshi

Michael Courtney

Haley Lozano-Sprague

Carter Rose

Allison Manuel

Julien Torgue

Nicolas Bozovic

Gwenaelle Nourry

Pascal Mirocha

J. Robert Chastain (Rob)

The Engineering and Technical Team at Orano Med is responsible for developing and maintaining the advanced technologies and systems used in the production of high-purity lead-212 (Pb-212) for targeted alpha therapy (TAT). This includes overseeing supply operations, managing technical services, ensuring the efficiency and reliability of production systems, and designing specialized equipment. The team also focuses on improving maintenance methods, executing digital industrial projects, and coordinating technical aspects to support cancer treatment innovation.

Engineering and Technical Team

Production and Operations

Quality Assurance and Control Team

Engineering and Technical Team

About

Team members

Other teams at Orano Med

Production and Operations

Quality Assurance and Control Team